XF-73 Drugs Research
Treatment of antibiotic-resistant biofilm and aggregate-associated infections (e.g., respiratory, dermal, oral mucositis)
ResearchActive
Key Facts
Indication
Treatment of antibiotic-resistant biofilm and aggregate-associated infections (e.g., respiratory, dermal, oral mucositis)
Phase
Research
Status
Active
Company
About Destiny Pharma
AMR Bio is a UK-based biotech focused on preventing life-threatening infections through its proprietary XF platform of novel antimicrobial compounds. Its lead asset, XF-73 Nasal, has completed Phase 2b trials for preventing post-surgical staphylococcal infections and is being prepared for Phase 3, with a projected blockbuster potential. The company employs a capital-efficient partnership model, aiming to out-license programs after generating proof-of-concept data, and is supported by prestigious grants from entities like the US NIH/NIAID.
View full company profile